A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

作者：Torikai, Hiroki; Reik, Andreas; Liu, Pei-Qi; Zhou, Yuanyue; Zhang, Ling; Maiti, Sourindra; Huls, Helen; Miller, Jeffrey C.; Kebriaei, Partow; Rabinovitch, Brian; Lee, Dean A.; Champlin, Richard E.; Bonini, Chiara; Naldini, Luigi; Rebar, Edward J.; Gregory, Philip D.; Holmes, Michael C.; Cooper, Laurence J. N.^*

来源：Blood, 2012, 119(24): 5697-5705.

DOI：10.1182/blood-2012-01-405365

• ZINC-FINGER NUCLEASES
• GRAFT-VERSUS-LEUKEMIA
• ADOPTIVE IMMUNOTHERAPY
• GENE DISRUPTION
• IN-VIVO
• PERSISTENCE
• THERAPY
• SYSTEM
• MEMORY
• MALIGNANCIES

Clinical-grade T cells are genetically modified ex vivo to express a chimeric antigen receptor (CAR) to redirect specificity to a tumor associated antigen (TAA) thereby conferring antitumor activity in vivo. T cells expressing a CD19-specific CAR recognize B-cell malignancies in multiple recipients independent of major histocompatibility complex (MHC) because the specificity domains are cloned from the variable chains of a CD19 monoclonal antibody. We now report a major step toward eliminating the need to generate patient-specific T cells by generating universal allogeneic TAA-specific T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR(+) T cells to eliminate expression of the endogenous alpha beta T-cell receptor (TCR) to prevent a graft-versus-host response without compromising CAR-dependent effector functions. Genetically modified T cells were generated using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of alpha or beta TCR chains with designer zinc finger nucleases. We show that these engineered T cells display the expected property of having redirected specificity for CD19 without responding to TCR stimulation. CAR(+)TCR(neg) T cells of this type may potentially have efficacy as an off-the-shelf therapy for investigational treatment of B-lineage malignancies. (Blood. 2012;119(24):5697-5705)

• 出版日期2012-6-14